Breast Cancer Index (BCI) Registry

Condition(s) studied

Investigational drug(s) / intervention(s)

Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test: The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.

Study summary

The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy.

Eligibility

Primary outcome measure(s)

• To determine BCI test performance by evaluating the long-term outcome of BCI risk groups over the follow-up period. — 5 Years
• To determine medication adherence in patients undergoing extended endocrine therapy. — 5 Years
  Patients will be asked to complete a Medication Adherence Questionnaire during routine follow-up visits. Medication adherence scores over time will be evaluated in patients that are recommended for or elect to continue treatment to complete 10 years of adjuvant endocrine therapy.

Trial sites (105)

+ 65 more sites — see the full list on the official registry below.

Other trials for the same condition